Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7531577 | 0.97 | CACNA1B (0.51) | CACNA1BEPHX2 | |
| SCHEMBL6930278 | 0.90 | CACNA1B (0.49) | CACNA1BEPHX2 | |
| SCHEMBL6931116 | 0.90 | CACNA1B (0.58) | CACNA1B | |
| SCHEMBL6931175 | 0.89 | CACNA1B (0.51) | CACNA1BEPHX2 | |
| SCHEMBL7527590 | 0.88 | CACNA1B (0.68) | CACNA1B | |
| SCHEMBL4510068 | 0.88 | CACNA1B (0.59) | CACNA1B | |
| SCHEMBL4502482 | 0.88 | CACNA1B (0.59) | CACNA1B | |
| SCHEMBL7749181 | 0.85 | CACNA1B (0.49) | CACNA1BEPHX2 | |
| SCHEMBL6929492 | 0.84 | CACNA1B (0.55) | CACNA1B | |
| SCHEMBL6924155 | 0.83 | CACNA1B (0.53) | CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610717-B2 | Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease | AJINOMOTO CO., INC. (JP) | 2003-08-26 | — | — | US | disclosed |
| US-6610717-B2 | Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease | AJINOMOTO CO., INC. (JP) | 2003-08-26 | — | — | US | disclosed |
| US-6610717-B2 | Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease | AJINOMOTO CO., INC. (JP) | 2003-08-26 | — | — | US | disclosed |
| US-20020193605-A1 | New dihydropyridine derivatives | AJINOMOTO CO. INC (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-1191022-A1 | NOVEL DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193605-A1 | New dihydropyridine derivatives | CACNA1B, CACNA1D, CACNA1C | CACNA1B 1/4885EPHX2 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.